CLINICAL TRIALS PROFILE FOR TRIGLIDE
✉ Email this page to a colleague
All Clinical Trials for TRIGLIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01752842 ↗ | Lipid Biomarkers for Diabetic Heart Disease | Completed | Leducq Foundation | N/A | 2013-03-01 | This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease. |
| NCT01752842 ↗ | Lipid Biomarkers for Diabetic Heart Disease | Completed | National Heart, Lung, and Blood Institute (NHLBI) | N/A | 2013-03-01 | This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease. |
| NCT01752842 ↗ | Lipid Biomarkers for Diabetic Heart Disease | Completed | National Institutes of Health (NIH) | N/A | 2013-03-01 | This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease. |
| NCT01752842 ↗ | Lipid Biomarkers for Diabetic Heart Disease | Completed | Washington University School of Medicine | N/A | 2013-03-01 | This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease. |
| NCT03829514 ↗ | Fenofibrate in Type 2 Diabetes | Completed | Medical University of South Carolina | Phase 4 | 2019-02-04 | Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopathy offers an important translational research opportunity. The investigator's global proteomic study will provide new clues as to how fenofibrate protects vulnerable tissues, and will spur discovery of targets for new therapeutic interventions. |
| NCT06191133 ↗ | Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma | Not yet recruiting | Lindsay Ferguson, MD | Phase 1 | 2024-08-01 | Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRIGLIDE
Condition Name
Clinical Trial Locations for TRIGLIDE
Trials by Country
Clinical Trial Progress for TRIGLIDE
Clinical Trial Phase
Clinical Trial Sponsors for TRIGLIDE
Sponsor Name
